Glatiramer Acetate: payments to doctors
Payments that named Glatiramer Acetate as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $98K
- Providers
- 135
- Transactions
- 233
- Average per transaction
- $421
The per-transaction average — $421 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 135 providers the average total is $727, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Mylan Institutional Inc. | $49,187 | 50.1% |
| Mylan Specialty L.p. | $17,589 | 17.9% |
| Mylan Inc. | $12,769 | 13.0% |
| Viatris Specialty LLC | $10,660 | 10.9% |
| Mylan Pharmaceuticals Inc. | $7,900 | 8.1% |